8 chapters across the catalog
Ozempic Holiday Vacation, Weight Loss Drug Costs
Users of weight loss drugs like Ozempic and Wegovy are reportedly taking "vacations" from the medication during the holidays to enjoy festive meals without nausea. Some users also cite the high financial cost of the drugs as a reason to stretch their supply to afford Christmas presents. The hosts suggest this media narrative is a ploy to get the drugs covered by Medicare.
Ozempic Personality Side Effects, Suicidal Ideation Reports
Users of weight-loss drugs like Ozempic and Mounjaro are reporting a new side effect dubbed "Ozempic personality," characterized by mood changes, anxiety, and a loss of joy. While the FDA found no direct link to suicidal thoughts, it stated it could not rule out a small risk. GNC has announced a dedicated section for products to manage the drugs' side effects, such as muscle mass loss and GI issues.
Weight Watchers Pivot to Obesity Care Management
Weight Watchers CEO Seema Sistani apologizes for the company's past focus on willpower, now framing obesity as a "chronic medical condition" requiring pharmaceutical intervention. The hosts analyze this as a shift toward "obesity care management" following Weight Watchers' acquisition of a telehealth service to prescribe drugs like Mounjaro.
Mounjaro vs. Ozempic and the Medicare Coverage Push
A report comparing Mounjaro and Ozempic identifies Mounjaro as the "clear winner" for weight loss. The hosts argue that the pharmaceutical industry is lobbying for Medicare to cover these expensive drugs by reclassifying obesity as a disease, which would force private insurers to follow suit and create a massive taxpayer-funded revenue stream.
Weight Loss Drugs and the Thanksgiving "Game Changer"
Media reports are framing weight loss drugs like Ozempic and Mounjaro as "game changers" for the Thanksgiving holiday, as users report a decreased interest in traditional feasting. Walmart's CEO noted that customers on these medications are buying less food, prompting the food industry to consider smaller portion sizes. The hosts critique the promotion of these drugs as a way to "increase energy" for the holidays.
Weight Loss Drug Marketing, Manjaro Success Stories
The FDA recently approved Zepbound, a new version of the diabetes drug Mounjaro, specifically for weight loss. Media reports have featured success stories, such as a 30-year-old woman who lost 125 pounds on the medication. While the drugs show promise for reducing inflammation and heart disease risk, experts warn they are not intended for casual weight loss and carry unknown long-term risks, especially given their high monthly cost of $1,300.
Manufacturers Novo Nordisk and Eli Lilly are facing lawsuits over claims that popular weight loss drugs Ozempic and Mounjaro cause severe stomach paralysis. A Louisiana woman alleges the drugs led to violent illness and emergency room visits. Despite these legal challenges, demand for GLP-1 agonists remains high, even as some insurance systems, like the University of Texas, begin to limit coverage.
The "fat affirmation" movement on social media is criticized for labeling intentional weight loss as "fatphobic." A mental health professional on TikTok claimed that 99.9% of weight loss efforts are rooted in bigotry. Concurrently, the pharmaceutical industry is rebranding diabetes medications like Mounjaro and Ozempic as obesity treatments, despite concerns about the loss of lean body mass and "Ozempic face."
